WO2012028925A2 - An improved process for the preparation of telmisartan - Google Patents

An improved process for the preparation of telmisartan Download PDF

Info

Publication number
WO2012028925A2
WO2012028925A2 PCT/IB2011/001973 IB2011001973W WO2012028925A2 WO 2012028925 A2 WO2012028925 A2 WO 2012028925A2 IB 2011001973 W IB2011001973 W IB 2011001973W WO 2012028925 A2 WO2012028925 A2 WO 2012028925A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
formula
propyl
ml
telmisartan
Prior art date
Application number
PCT/IB2011/001973
Other languages
French (fr)
Other versions
WO2012028925A3 (en
Inventor
Nanoranjan Choudary Boyapati
Sridhar Kokkalla
Naga Raju Koneti
Chakrapani Lakkoju
Sambhu Prasad Sarma Mallela
Original Assignee
Ogene Systems (I) Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN2561CH2010 priority Critical
Priority to IN2561CHE2010 priority
Application filed by Ogene Systems (I) Pvt Ltd filed Critical Ogene Systems (I) Pvt Ltd
Publication of WO2012028925A2 publication Critical patent/WO2012028925A2/en
Publication of WO2012028925A3 publication Critical patent/WO2012028925A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical

Abstract

Methyl-4-(butyramido)-3-methyl-5-nitrobenzoate is treated with sulphur containing reducing agent to give methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate, which is further hydrolyzed to the corresponding acid, 2-n-propyl-4-methyl-6- carboxy benzimidazole. The critical intermediate l,4'-dimethyl-2'-propyl-lH,3'H- 2,6'-bisbenzimidazol (DMPBB) is prepared by treating the above acid with N- mehtyl-o-phenylenediamine dihydrochloride under acidic conditions. Reaction of 4'-halomethylbiphenyl-2-carboxylic acid alkyl ester with DMPBB in presence of base to give Telmisartan ester which is further converted to Telmisartan of Formula (I).

Description

AN IMPROVED PROCESS FOR THE PREPARATION OF

TELMISARTAN FIELD OF INVENTION

The present invention relates to an improved process for the preparation of [4'-(2- n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 - ylmethyl]biphenyl-2-carboxylic acid (Telmisartan) of Formula I.

Formula I

Figure imgf000002_0001

BACKGROUND OF THE INVENTION

Telmisartan is the INN (International Nonproprietary Name) for the compound 4'- [2-n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 - ylmethyl]biphenyl-2-carboxylic acid. (CAS Registry No. 144701-48-4) The empirical formula of telmisartan is C33H3oN402 and its molecular weight is 514.63. The molecular structure of telmisartan is represented by Formula I.

The synthesis of Telmisartan was first described in U.S. Pat. No. 5,591,762 (hereinafter the '762 patent) by hydrolysis of the tertiary-butyl ester precursor of Telmisartan, in particular, tert-butyl 4'[2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazol- 1 -ylmethyl]biphenyl-2-carboxylic acid using trifluoroacetic acid in N,N-dimethylformamide (DMF).

Figure imgf000003_0001

Telmisartan

Chinese patent application CN 1412183 (hereinafter the Ί83 application) describes a process for preparing Telmisartan, which includes reacting 2-n-propyl-4-methyl- 6-(l-methylbenzimidazol-2-yl)benzimidazole with 4'-(bromomethyl)-[l,l '- biphenyl]-2 -carbonitrile to afford the carbonitrile derivative of Telmisartan, i.e., 4'- [ 1 ,4 ' -dimethyl-2 ' -propyl [2,6' -bi- 1 H-benzimidazol] - 1 ' -yl-)methyl] -[1,1 '-biphenyl] - -carbonitrile, followed by hydrolysis of the cyano group to afford Telmisartan.

Figure imgf000003_0002

Chinese patent application CN 1344712 (hereinafter the '712 application) describes the preparation of Telmisartan by reacting 2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazole with 4'-(bromomethyl)-[l,r-biphenyl]-2- carboxylic acid methyl or ethyl ester via nucleophilic substitution, to give the carboxylic ester derivatives of Telmisartan, followed by hydrolysis to afford Telmisartan.

Figure imgf000004_0001

WO 2006/044648 describes synthetic route, which is similar to- the synthesis described in the '712 application, using a low boiling solvent and a PTC.

In general, Telmisartan is manufactured and supplied in its free acid form. However, as described in US 6,410,742 crystalline Telmisartan apparently exists in two polymorphic forms A and B, which have different melting points. Both of these forms are apparently very poorly soluble in aqueous systems at the physiological pH range 1 to 7, in the gastro-intestinal tract.

The critical step in the manufacturing process of Telmisartan is the n-alkylation of 2-n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)- 1 H-benzimidazole (DMPBB) of formula VII with 4'-halomethylbiphenyl-2-carboxylic acid alkyl ester of formula VIII. The synthesis of substituted benzimidazoles is desirably carried out by first reducing methyl-4-(butyramido)-3-methyl-5-nitrobenzoate of formula III under various catalytic hydrogenation conditions to yield methyl-3-amino-4- (butyramido)-5-methylbenzoate. The reduction step is carried out under different conditions using Raney Ni/H2, Pd-C/H2, Sn(II)chloride and Fe/HCl, Sn/HCl as per the literature known procedures.

Methyl-3-amino-4-(butyramido)-5-methylbenzoate of formula III is cyclized under variety of basic and acidic conditions to yield methyl-4-methyl-2-propyl-lH- benzimidazole-6-carboxylate of formula IV as per the prior art methods.

The critical intermediate l,4'-dimethyl-2'-propyl-lH,3'H-2,6'-bisbenzimidazol (DMPBB) of Formula VII is prepared in the prior art as per the following methods: US 5,591,762 describes methyl-4-(butyramido)-3-methyl-5-nitrobenzoate is reduced under catalytic hydrogenation condition using Pd/C in methanol to give the substituted aniline derivative. This aniline derivative is converted to methyl-4- methyl-2-propyl-lH-benzimidazole-6-carboxylate using acetic acid. The crude product obtained is hydrolyzed and recrystallized from isopropanol to give benzimidazole carboxylic acid, which is then converted into the desired 2-n-propyl- 4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazole with 2-methylamino- aniline by cyclization.

US 2007/0037986 describes a process for preparing l,7'-dimethyl-2'-propyl-2,5'- bi-lH-benzimidazole, by reacting N-methyl-o-phenylenediamine with 2-propyl-4- methyl-lH-benzimidazole-6-carboxylic acid wherein the coupling and cyclization is achieved using 1,3,5-triazine and tertiary amine.

DMPBB may be prepared by mixing 2-propyl-4-methyl-lH-benzimidazole-6- carboxylic acid with N-methyl-o-phenylene-diamine dihydrochloride with polyphospharic acid as disclosed in J. Med. Chem. 1993, 36(25), 4040-51, international patent application WO 2000/0063158, and US 2003/0139608, are hereby incorporated by reference for their disclosure of processes, which involves two-step process involving tedious work-up and purification procedures. WO 2009/133122 describes the method for the preparation of l,7'-dimethyl-2'- propyl-2,5'-bi-lH-benzimidazole by the conversion of N-methyl-o-phenylene- diamine with 2-propyl-4-methyl-lH-benzimidazol-6-carboxylic acid using phosphourus pentoxide in methane sulphonic acid solvent, at a temperature range from 110-160 °C.

Reduction of nitro groups, which is the first step in the above mentioned syntheses is achieved with a wide variety of reagents namely catalytic hydrogenation using metal supported catalysts like Pd/C, Rh C, Pt/C and dissolved metal reductions like Sn/HCl, Mercury amalgam, Sn(II) Chloride etc.

However, these methods suffer from the disadvantage that the catalysts used are very expensive and manufacturing methods involve workup using organic solvents. These facts affect the commercial viability of manufacturing process substantially. There is a need for better synthetic methodologies for the manufacture of 1,4'- dimethyl-2'-propyl-lH,3'H-2,6'-bisbenzimidazol (DMPBB) of formula VII.

We have now realized an alternate method for the synthesis of methyl-4-methyl-2- propyl-lH-benzimidazole-6-carboxylate of formula IV involving a single pot reduction and cyclodehydration as per Scheme given below:

Scheme

Figure imgf000006_0001
OBJECTIVE OF THE INVENTION

The main objective of the present invention is to provide an improved process for the preparation of [4'-(2-n-propyl-4-methyl-6-(l-methylbenzimidazol-2- yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid (Telmisartan), which is simple, industrially applicable and economically viable.

SUMMARY OF THE INVENTION The present invention relates to an improved process for the preparation of [4'-(2- n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 - ylmeth l]biphenyl-2-carboxylic acid (Telmisartan) of formula I,

Formula I

Figure imgf000007_0001
which comprises:

a) treating methyl-4-(butyramido)-3-methyl-5-nitrobenzoate of formula II,

Formula II

Figure imgf000007_0002
with sulphur containing reducing agent in water or an organic solvent or a mixture of water and an organic solvent to give a compound of formula IV, Formula IV
Figure imgf000008_0001
which is formed by insitu reduction and cyclodehydration process at temperature ranging 20-120 °C, preferably in the range of 80-100 °C; b) reaction mass from step (a) is basified with an inorganic base to pH 1 1 -12 and heated at temperature ranging from 20-100 °C preferably in the range of 80-100 °C to convert ester of formula IV to the corresponding acid of formula V,

(OR)

converting the isolated ester of formula IV from step (a) with an aqueous base in presence or absence of an organic co-solvent at a temperature ranging 20-100 °C, preferably in the range of 80-100 °C to corresponding acid of formula V;

Formula V

Figure imgf000008_0002
c) cyclizing the corresponding acid of formula V with N-methyl-o- phenylenediamine dihydrochloride in the presence of an acid to give a compound of formula VII

Formula VII

Figure imgf000008_0003
alkylation of compound of formula VII with 4'-halomethylbiphenyl-2- carboxylic acid alkyl ester of formula VIII, Formula VIII
Figure imgf000009_0001
wherein X represents Br, CI, I and R represents straight or branched chain C,-C4 alkyl;

to give Telmisartan ester (IX),

Formula IX

Figure imgf000009_0002
wherein R represents straight or branched chain C1-C4 alkyl;

e) hydrolysis of Telmisartan ester (IX) to give Telmisartan.

DETAILED DESCRIPTION OF THE INVENTION

N-Ortho nitro anilines are cyclized to 2-substituted benzimidazoles in one pot using reagents like Pd-C/methanol/H2 gas as described in Organic Process Research & Development 2007, 11, 81-85, Sn/HCl in Chemische Berichte 1872, 5, 920, Fe/HCl in WO 2004/108686 and Hydrazine/Raney Ni in Journal of Heterocyclic chemistry 2003, 40, 1107-1112. These reductions suffer from major draw backs of toxic inorganic byproducts and random purification procedures using column chromatography.

We have now realized methyl-4-butyramido-3-methyl-5-nitrobenzoate (II) is reacted with reducing agent selected from derivatives of sulphur like sodium sulfite, sodium sulphide, sodium dithionite, sodium metabisulfite etc. in water or an organic solvent or a mixture of water and an organic solvent with a temperature ranging 20-120 °C. Insitu reduction and cyclodehydration takes place in one-step giving methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (IV). The cyclizing agent is sodium dithionite, a cheap alternate to the costly catalysts used in the reduction process of nitro compound. The insitu reduction and cyclization is carried out in water or an organic solvent or a mixture of water and an organic solvent, wherein an organic solvent selected from alcohol such as methanol, IP A, ethanol, butanol or ether such as dioxane or THF or dipolar aprotic solvent such as DMF, DMA, DMSO, NMP, sulfolane.

The above mentioned process can be carried out in presence of acids such as hydrochloric acid, sulphuric acid, acetic acid, propionic acid, benzoic acid etc., in water or an organic solvent or a mixture of water and an organic solvent.

The above mentioned process can also be carried out in presence of bases selected from alkali earth metal or alkaline earth metal hydroxides, carbonates, bicarbonates such as sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, magnesium hydroxide, calcium hydroxide, strontium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate etc., in water or an organic solvent or a mixture of water and an organic solvent.

According to a particular embodiment, insitu reduction-cyclodehydration process of compound of formula II is treated with hydrose (Sodium dithionite), in aqueous solvent system as previously described at a temperature ranging from 20-120 °C, preferably 80-100 °C for a period of 20-48 hrs.

After completion of the insitu reduction-cyclodehydration, product is isolated from the reaction mass by neutralizing. Hydrolysis of methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (IV) with base selected from inorganic bases of alkali earth metal or alkaline earth metal hydroxides, carbonates, bicarbonates such as sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, magnesium hydroxide, calcium hydroxide, strontium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate etc., preferably sodium hydroxide, in a solvent selected from ethanol, methanol, isopropyl alcohol, preferably methanol at a temperature of 80 °C gives 2-n-propyl- 4-methyl-6-carboxy benzimidazole. The acid, 2-n-propyl-4-methyl-6-carboxy benzimidazole which is obtained by the above process is cyclized with N-methyl-o- phenylenediamine in presence of an acid selected from polyphosphoric acid, p- toluenesulfonic acid, sulphuric acid, acetic acid, preferably polyphosphoric acid at a temperature ranging 80-130 °C, preferably 120-130 °C, gives l,4'-dimethyl-2'- propyl- 1 H,3 'H-2,6'-bisbenzimidazol (VII).

Condensation of l,4'-dimethyl-2'-propyl-lH,3'H-2,6'-bisbenzimidazol (VII) with 4'-halomethylbiphenyl-2-carboxylic acid alkyl ester (VIII) in presence of base selected from potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, preferably sodium hydroxide in a solvent selected from DMF, DMSO, THF, preferably DMF at a temperature ranging 0-60 °C, preferably 20-30 °C, to produce 4'-(l,4'-dimethyl-2'-propyl-lH-[2,5']benzimidazolyl-3'- ylmethyl)biphenyl-2-carboxylic acid methyl ester (IX) (Telmisartan ester).

Further hydrolysis of 4,-(l,4'-dimethyl-2'-propyl-lH-[2,5']benzimidazolyl-3'- ylmethyl)biphenyl-2-carboxylic acid methyl ester (IX) in presence of base preferably sodium hydroxide and a solvent preferably methanol to produce Telmisartan.

The following examples illustrate the nature of the invention and are provided for illustrative purposes only and should not be construed to limit the scope of the invention. Experiments:

Experiment I: Preparation of methyl-4-methyl-2-propyl-lH-benzimidazole-6- carboxylate (Imidazole Ester).

Example 1:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (50 gm, 0.178 moles), was suspended in water (300 ml) and heated to 70-80 °C. A suspension of sodium dithionite (108.7 gm, 0.536 moles) in water (300 ml) was added gradually to the above mass and the temperature is raised to 90-100 °C. After the reaction completed, the pH of the reaction mixture was adjusted to 9-10 and extracted with ethyl acetate (3x200 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH-benzimidazole-6- carboxylate (40 gms, Yield : 96.6 %) of formula IV.

Example 2:

To a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles) in methanol (20 ml) was added a suspension of sodium dithionite (10.87 gm, 0.0536 moles) in water (15 ml) at 70-80 °C. Then the temperature was raised to 90-100 °C. After completion of the reaction, methanol was evaporated under reduced pressure. Water (100 ml) was added to the residue and pH was adjusted to 9-10 and extracted with ethyl acetate (70 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl- lH-benzimidazole-6-carboxylate (3.9 gms, Yield: 95%) of formula IV.

Example 3:

A suspension of sodium dithionite (108.7 gm, 0.536 moles) in water (150 ml) was added gradually to a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (50 gm, 0.178 moles) in isopropanol (200 ml) at 70-80 °C. Then the temperature was raised to 90-100 °C. After completion of the reaction, Isopropanol was evaporated under reduced pressure. To the residue was added water (500 ml) and pH was adjusted to 9-10 and extracted with ethyl acetate (600 ml), and the combined organic layer was concentrated under reduced pressure to give methyl-4- methyl-2-propyl-lH-benzimidazole-6-carboxylate (33 gms, Yield: 79.6 %) of formula IV.

Example 4:

A suspension of sodium dithionite (108.7 gm, 0.536 moles) in water (150 ml) was added gradually to a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (50 gm, 0.178 moles) in n-butanol (200 ml) at 70-80 °C. Then the temperature was raised to 90-100 °C. After completion of the reaction, n-butanol was distilled out under reduced pressure. Water (400 ml) was added to the residue and pH was adjusted to 9-10 and extracted with ethyl acetate (3x200 ml) and the combined organic layer was concentrated under reduced pressure to afford methyl-4-methyl- 2-propyl-lH-benzimidazole-6-carboxylate (31 gm, Yield: 75 %) of formula IV.

Example 5:

To a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles) in toluene (20 ml), was gradually added sodium dithionite (10.87 gm, 0.0536 moles) in water (20 ml) at 70-80 °C. Then the temperature is raised to 90-100 °C. After completion of the reaction, toluene was evaporated under reduced pressure. Water (100 ml) was added to the residue and pH was adjusted to 9-10 and extracted with ethyl acetate (2x60 ml) and the combined organic layer was concentrated under reduced pressure to provide methyl-4-methyl-2-propyl-lH- benzimidazole-6-carboxylate (1 gm, Yield: 24 %) of formula IV.

Example 6:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles), was suspended in MeOH (25 ml) and heated to 70-80 °C. Sodium dithionite (10.87 gm, 0.0536 moles) was added gradually to the reaction mixture and the temperature was raised to 60-65 °C. After completion of the reaction, methanol was evaporated under reduced pressure. To the residue was added water (70 ml) and pH was adjusted to 9-10 and extracted with ethyl acetate (2x50 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2- propyl-lH-benzimidazole-6-carboxylate (3 gm, Yield: 96.6 %) of formula IV.

Example 7:

Sodium dithionite (6.52 gm, 0.0375 moles) was added gradually to a solution of 4- butyramido-3-methyl-5-nitro methyl benzoate (II) (3 gm, 0.0107moles) in DMF (15 ml) at 70-80 °C. Then the temperature was maintained at 90-100 °C. After the reaction completed, the reaction mixture was poured into ice cold water (150 ml) and the pH of the reaction mass was adjusted to 9-10 and extracted with ethyl acetate (2x50 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (1.8 gm, Yield: 72.4 %) of formula IV.

Example 8:

Sodium dithionite (6.52 gm, 0.0375 moles) was added gradually to a solution of 4- butyramido-3-methyl-5-nitro methyl benzoate (II) (3 gm, 0.0107moles) in DMSO (10 ml) and heated to 70-80 °C. Then the temperature of the reaction was raised to 90-100 °C. After completion of the reaction, the reaction mixture was poured into ice cold water (150 ml) and the pH of the reaction mass was adjusted to 9-10 and extracted with ethyl acetate (2X75 ml) and the combined organic layer was concentrated under reduced pressure to afford methyl -4-methyl-2 -propyl- \H- benzimidazole-6-carboxylate (2.2 gms, Yield: 90 %) of formula IV.

Example 9:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (3 gm, 0.0107 moles), was suspended in DMA (15 ml) and heated to 70-80 °C. Sodium dithionite (6.52 gm, 0.0375 moles) was added gradually to the reaction mixture and the temperature was raised to 90-100 °C. After reaction complies, the reaction mixture was poured into ice cold water (150 ml) and the pH of the reaction mass was adjusted to 9-10 and extracted with ethyl acetate (2X60 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2 -propyl- 1H- benzimidazole-6-carboxylate (1 gm, Yield: 40.2 %) of formula IV.

Example 10:

To a suspension of sodium dithionite (10.87 gm, 0.0536 moles) in water (50 ml) was added 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles) in 10% DMF/H20 (100 ml) at 70-80 °C. Then the temperature was maintained at 90-100 °C. After completion of the reaction, the reaction mixture was poured into ice cold water (200 ml) and the reaction mass pH was adjusted to 9-10 and extracted with ethyl acetate (2X50 ml) and the combined organic layer was concentrated under reduced pressure to afford methyl -4-methyl-2-propyl-lH- benzimidazole-6-carboxylate (3.5 gms, Yield: 84.5 %) of formula IV.

Example 11:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (3 gm, 0.0107 moles), was suspended in 10% DMSO/H20 (100 ml) and heated to 70-80 °C. Sodium dithionite (6.52 gm, 0.0375 moles) suspended in water (20 ml) was added gradually to the above reaction mass and the temperature maintained at 90-100 °C. After reaction complies, the reaction mixture was poured into ice cold water (150 ml) and the reaction mass pH was adjusted to 9-10 and extracted with ethyl acetate (2X50 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (2.1gms, Yield: 84.4 %) of formula IV. Example 12:

To a suspension of sodium dithionite (10.87 gm, 0.0536 moles) in water (40 ml) was gradually added to a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles) in Toluene (50 ml) at 70-80 °C. Then the temperature of the reaction mixture was maintained at 90-100 °C. Tetrabutylammonium bromide (0.5 gm) was added to the reaction mass as a PTC. After completion of the reaction, toluene was evaporated under reduced pressure. To the residue water (100 ml) was added and pH was adjusted to 9-10 and extracted with ethyl acetate (2X60 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH- benzimidazole-6-carboxylate (3 gms, Yield: 72.4 %) of formula IV.

Example 13:

To a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gm, 0.0178 moles) in methanol (50 ml) at 70-80 °C, was gradually added a suspension of sodium dithionite (10.87 gm, 0.0536 moles) in water (40 ml). Then the temperature of the reaction mixture was maintained at 90-100 °C. Tetrabutylammonium bromide (0.5 gm) was added as a PTC to the above reaction mass. After completion of the reaction, methanol was evaporated under reduced pressure. Water (100 ml) was added to the residue and pH was adjusted to 9-10 and extracted with ethyl acetate (2x60 ml) and the combined organic layer was concentrated under reduced pressure to give methyl -4-methyl -2 -propyl- \H- benzimidazole-6-carboxylate (3 gms, Yield: 72.4 %) of formula IV.

Example 14:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (3 gm, 0.0107 moles), was suspended in 10 % aqueous acetic acid (50 ml) and heated to 70-80 °C. A suspension of sodium dithionite (6.52 gm, 0.0375 moles) in water (20 ml) was added gradually to the reaction mixture and the temperature was raised to 90-100 °C. After completion of the reaction, the reaction mixture pH was adjusted to 9-10 and extracted with ethyl acetate (2X60 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH- benzimidazole-6-carboxylate (2.1 gms, Yield: 84.4 %) of formula IV.

Example 15:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (20 gm, 0.071 moles), was suspended in methanol (100 ml) and heated to 70-80 °C. Sodium dithionite (43.5 gm, 0.248 moles) was suspended in saturated sodium bicarbonate solution (60 ml) was added gradually to the reaction mixture and the temperature was raised to 90- 100 °C. After completion of the reaction, methanol was evaporated under reduced pressure. The pH of the reaction mass was adjusted to 9-10 and extracted with ethyl acetate (2X75 ml) and the combined organic layer was concentrated under reduced pressure to give methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (16 gms, Yield: 96.5 %) of formula IV.

Example 16:

To a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (20 gm, 0.071 moles) in isopropanol (80 ml) at 70-80 °C was added sodium dithionite (43.5 gm, 0.248 moles) in saturated bicarbonate solution (60 ml) and the temperature of the reaction mass was maintained at 90-100 °C. After reaction complies, isopropanol was evaporated under reduced pressure. The reaction mass pH was adjusted to 9-10 and extracted with ethyl acetate (2x75 ml) and the combined organic layer was concentrated under reduced pressure to give methyl -4-methyl-2- propyl-lH-benzimidazole-6-carboxylate (10 gm, Yield: 60.3 %) of formula IV.

Example 17:

A solution of sodium sulfide (1.39 gm, 0.536 moles) in water (80 ml) was added gradually to a suspension of 4-butyramido-3-methyl-5-nitro methyl benzoate (II) (5 gms, 0.0178 moles) in water (30 ml) at 70-80 °C. Then the temperature of the reaction mass was maintained at 90-100 °C. After completion of the reaction, the pH of the reaction mixture was adjusted to 9-10 and extracted with ethyl acetate (500 ml) and the combined extracts were concentrated and the pure methyl-4- methyl-2-propyl-lH-benzimidazole-6-carboxylate (2 gms, Yield : 51.4 %) of formula IV was isolated by column chromatography. Experiment II: Preparation of 2-n-propyl-4-methyl-6-carboxy benzimidazole (V).

Example 1:

Methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (40 gms, 0.172 moles) was suspended in methanol (200 ml) and stirred for few minutes. Sodium hydroxide (13.76 gms, 0.344 moles) dissolved in water (50 ml) was added to the reaction mass and the temperature is maintained at 80°C. After completion of the reaction, methanol was evaporated under reduced pressure and water (100 ml) was added to the crude mass at 5-10 °C. Then adjusted the pH of the crude mass to 6- 6.5 and the obtained solid was filtered. The solid was washed with water and dried at temperature of 45-50 °C under vacuum (700 mm) to yield 2-n-propyl-4-methyl- 6-carboxy benzimidazole (30gms, Yield: 80 %).

Example 2:

To a suspension of methyl-4-methyl-2-propyl-lH-benzimidazoIe-6-carboxylate (2 gms, 0.0086 moles) in water (10 ml) was added aqueous sodium hydroxide solution (0.69 gms, 0.017 moles) and the temperature is maintained at 85-95 °C. After completion of the reaction, the reaction mass was cooled to room temperature and pH was adjusted to 6-6.5 with aqueous hydrogen chloride and the obtained solid was filtered. The solid was washed with water and dried at temperature of 45- 50 °C under vacuum (700 mm) to yield 2-n-propyl-4-methyl-6-carboxy benzimidazole (1.1 gms, Yield: 59 %).

Example 3:

Aqueous sodium hydroxide solution (1.68 gms, 0.042 moles, 10 ml) was added to a solution of methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (5 gms, 0.021 moles) in isopropanol (20 ml) and stir for few minutes. Then the temperature was raised to 85 °C. After reaction complies, isopropanol was evaporated under reduced pressure and water (75 ml) was added to the crude mass at 5-15 °C. Then the pH of the crude mass was adjusted to 6-6.5 and the obtained solid was filtered. The solid was washed with water and dried at temperature of 45-50 °C under vacuum (600 mm) to yield 2-n-propyl-4-methyl-6-carboxy benzimidazole (2.81 gms, Yield: 60%).

Example 4:

4-butyramido-3-methyl-5-nitro methyl benzoate (II) (10 gm, 0.036 moles), was suspended in water (60 ml) and heated to 70-80 °C. A suspension of sodium dithionite (21.75 gm, 0.124 moles) in water (60 ml) was added gradually to the above mass and the temperature is raised to 90-100 °C. After the reaction complies, the pH of the reaction mixture was adjusted to 10-11 and continued to stir at same temperature until the methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate disappears in TLC. Then the pH of the reaction mass adjusted to pH 6-6.5. The solid obtained was filtered and dried at 45-50 °C to afford 2-n-propyl-4-methyl-6- carboxy benzimidazole (7.5 gms, Yield: 96.4 %). Example 5:

To a solution of methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (2 gms, 0.0086 moles) in methanol (10 ml) was added aqueous potassium hydroxide solution (0.95 gms, 0.017 moles, in 5 ml) and the temperature is maintained at 80 °C. After completion of the reaction, methanol was evaporated under reduced pressure and water (50 ml) was added to the crude mass at 5-15 °C. Then adjusted the pH of the crude mass to 6-6.5 and the obtained solid was filtered. The solid was washed with water and dried at temperature of 45-50 °C under vacuum (600 mm) to yield 2-n-propyl-4-methyl-6-carboxy benzimidazole (1.22 gms, 64 %). Example 6:

An aqueous solution of sodium bicarbonate (2.1 gms, 0.026 moles, in 10 ml) was added to a solution of methyl-4-methyl-2-propyl-lH-benzimidazole-6-carboxylate (3 gms, 0.013 moles) in methanol (15 ml) and the temperature is maintained at 80 °C. After reaction complies, methanol was distilled off under reduced pressure and water (100 ml) was added to the crude mass at 5-15 °C. Then the pH of the crude mass was adjusted to 6-6.5 and the obtained solid was filtered. The solid was washed with water and dried at temperature of 45-50°C under vacuum (600 mm) to yield 2-n-propyl-4-methyl-6-carboxy benzimidazole (0.56gms, Yield: 20 %).

Experiment III: Preparation of 2-n-propyl-4-methyl-6-(l-methylbenzimidazol- 2-yl)-lH-benzimidazoIe (VII).

Example 1:

Orthophosphoric acid (210 gms) was taken in round bottomed flask and Ρ205 (210 gms) was added in portions with vigorous stirring. (Note: Sharp increase in temperature > 200 °C). The above mass is allowed to cool to 70 °C and 2-n-propyl- 4-methyl-benzimidazole-6-carboxylic acid (70 gms, 0.321 mol) was added slowly. Then N-methylbenzene-l,2-diamine hydrochloride (62.3 gms, 0.321 mol) was added in small portions at same temperature and then the temperature was raised to 125-130 °C. After completion, reaction was quenched with ice cold water (1 Lt), adjusted pH of the reaction mixture to 9-10 by the addition of aqueous ammonia solution. Obtained solid was filtered and washed with cold water until the pH of the filtrate becomes neutral. Then the crude solid was washed with hot water until colorless filtrate was observed. The crude solid was boiled in ethyl acetate (700 ml) for 2-3 hrs. The reaction mass was cooled and the suspension was filtered off and dried to yield 2-n-propyl-4-methyl-6-(l-methylbenzimidazol-2-yl)-lH- benzimidazole (V) (80 gms, Yield : 82 %).

Example 2:

2-n-Propyl-4-methyl-benzimidazole-6-carboxylic acid (7 gms) was taken in acetic acid at 70 °C. Then N-methylbenzene-l,2-diamine hydrochloride (6.3 gms) was added in portion wise at same temperature and then the temperature was raised to 1 10 °C. After completion, reaction was quenched with ice cold water (200 ml) and pH of the reaction mixture was adjusted to 9-10 by the addition of aqueous ammonia solution. The obtained solid was filtered and washed with cold water (3 x 100 ml) until the pH of the filtrate becomes neutral. The residue was dried at 50-55 °C under vacuum (700 mm) to give 2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)-lH-benzimidazole (V) (2 gms, Yield : 20 %). Experiment IV: Preparation of 4'-(l,4'-dimethyl-2'-propyl-lH- [2,5']benzimidazolyl-3'-ylmethyl)biphenyl-2-carboxylic acid methyl ester (IX).

Sodium hydroxide (10 gms, mol) dissolved in water (11 ml) was added to a round bottomed flask containing DMF (20 ml) at 0-5 °C. 2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)-lH-benzimidazole (55 gms, 0.181 mol) dissolved in DMF (200 ml) was added slowly to the above mass at same temperature and stirring was continued at the same temperature for 30 min. 4'-(bromomethyl)-[l,l'- biphenyl]-2-carboxylic acid methyl ester (55 gms, 0.181 mol) in 100 ml of DMF was added slowly to the above reaction mass at same temperature for 30 min. After the reaction was completed, the reaction mass was poured into ice cold water (1 Lt) with continuous stirring. The obtained precipitate was filtered and the wet cake was washed with cold water (1 Lt) and dried at room temperature to yield 4'-(l,4'- dimethyl-2' -propyl- 1 H-[2,5 ' ]benzimidazolyl-3 ' -ylmethyl)biphenyl-2-carboxylic acid methyl ester (88 gms, Yield : 92.1%).

Experiment V: Preparation of [4'-(2-n-propyl-4-methyl-6-(l- methylbenzimidazoI-2-yI)benzimidazoI-l-yImethyI]biphenyI-2-carboxyIic acid (I).

4' -( 1 ,4' -dimethyl-2 ' -propyl- 1 H- [2,5 ' ]benzimidazolyl-3 ' -ylmethyl)biphenyl-2- carboxylic acid methyl ester (90 gms, 0.170 mol) was taken in methanol (500 ml). 100 ml of 4 M sodium hydroxide solution was added and raised the temperature up to 80 °C. After the reaction was completed, methanol was distilled under vacuum and 500 ml of DM water was added to the reaction mass and extracted with ethyl acetate (3X150 ml). Entire aqueous layers were collected and cooled to 5-10 °C. The pH of above aqueous solution was adjusted to 6-6.5 using aqueous hydrochloric acid (IN HCl). The precipitated solid was filtered, washed with water and wet product was dried at 40-45 °C to yield [4'-(2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazol- 1 -ylmethyl]biphenyl-2-carboxylic acid (I). The crude solid was recrystallized from DMF and MeOH/H20 system, to give pure telmisartan. (81 gms, Yield: 92.4 %).

Claims

Claim
The present invention relates to an improved process for the preparation (2-n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 - y ) of formula I,
Formula I
Figure imgf000022_0001
which comprises:
a) treating methyl-4-(butyramido)-3-methyl-5-nitrobenzoate of formula II,
Formula II
Figure imgf000022_0002
with sulphur containing reducing agent in water or an organic solvent or a mixture of water and an organic solvent to give a compound of formula IV,
Formula IV
Figure imgf000022_0003
which is formed by insitu reduction and cyclodehydration process at temperature ranging 20-120 °C, preferably in the range of 80-100 °C; b) reaction mass from step (a) is basified with an inorganic base to pH 11-12 and heated at temperatures ranging 20-100 °C, preferably in the range of 80-100 °C to convert ester of formula IV to the corresponding acid of formula V,
(OR)
converting the isolated ester of formula IV from step (a) with an aqueous base in presence or absence of an organic co-solvent at a temperature ranging 20-100 °C, preferably in the range of 80-100 °C to corresponding acid of formula V;
Formula V
Figure imgf000023_0001
c) cyclizing the corresponding acid of formula V with N-methyl-o- phenylenediamine dihydrochloride in the presence of an acid to give a compound of formula VII;
Figure imgf000023_0002
d) alkylation of compound of formula VII with 4'-halomethylbiph<
carboxylic acid alk l ester of formula VIII,
Formula VIII
Figure imgf000023_0003
wherein X represents Br, CI, I and R represents straight or branched chain C,-C4 alkyl;
in the presence of base in an organic solvent to give Telmisartan ester (IX), Formula IX
Figure imgf000024_0001
wherein R represents straight or branched chain C1-C4 alkyl;
e) hydrolysis of Telmisartan ester (IX) to give Telmisartan.
A process according to claim 1, sulphur containing reducing agent used in step (a) is selected from sodium sulfite, sodium sulfide, sodium dithionite, sodium metabisulfite.
A process according to claim 1, insitu reduction and cyclodehydration is carried out in water or an organic solvent or a mixture of water and an organic solvent, wherein organic solvent is selected from alcohol such as methanol, IP A, ethanol, butanol or ether such as dioxane, THF or dipolar aprotic solvent such as DMF, DMA, DMSO, NMP, sulfolane.
A process according to claim 1, insitu reduction and cyclodehydration is carried at a temperature ranging 20-120°C, preferably 80-100°C.
A process according to claim 1, wherein a base used in step (b) and (d) is inorganic base selected from alkali earth metals or alkaline earth metals hydroxides, carbonates, bicarbonates such as sodium hydroxide, potassium hydroxide, cesium hydroxide, barium hydroxide, magnesium hydroxide, calcium hydroxide, strontium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate etc., preferably sodium hydroxide.
6. A process according to claim 1, wherein an organic co-solvent used in step (b) is selected from ethanol, methanol, and isopropyl alcohol.
7. A process according to claim 1, wherein an acid in step (c) is selected from PPA, PTSA, H2S04> CH3COOH.
8. A process according to claim 1, wherein a solvent used in step (d) is selected from DMF, DMSO, THF. 9. A process according to claim 1, Telmisartan ester is hydrolyzed in presence of base and a solvent to produce Telmisartan.
10. According to claim 1 or 9, wherein base is sodium hydroxide and a solvent is methanol.
Dated 011.
Figure imgf000025_0001
(MANAGING DIRECTOR)
PCT/IB2011/001973 2010-09-03 2011-08-29 An improved process for the preparation of telmisartan WO2012028925A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2561CH2010 2010-09-03
IN2561CHE2010 2010-09-03

Publications (2)

Publication Number Publication Date
WO2012028925A2 true WO2012028925A2 (en) 2012-03-08
WO2012028925A3 WO2012028925A3 (en) 2012-04-26

Family

ID=44801033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/001973 WO2012028925A2 (en) 2010-09-03 2011-08-29 An improved process for the preparation of telmisartan

Country Status (1)

Country Link
WO (1) WO2012028925A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014067237A1 (en) * 2012-10-31 2014-05-08 上海特化医药科技有限公司 Telmisartan preparation method and intermediate thereof
JP2015160810A (en) * 2014-02-26 2015-09-07 株式会社トクヤマ METHOD OF PRODUCING 4-METHYL-6(1-METHYLBENZIMIDAZOL-2-YL)-2-n-PROPYL-1H-BENZIMIDAZOLE
CN104974096A (en) * 2015-07-07 2015-10-14 威海迪嘉制药有限公司 Preparation method of telmisartan intermediate

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
WO2000063158A1 (en) 1999-04-17 2000-10-26 Boehringer Ingelheim Pharma Kg Method for nitrating aniline derivatives
CN1344712A (en) 2001-07-30 2002-04-17 中国科学院上海药物研究所 Synthesis path of Timisatem
US6410742B1 (en) 1999-01-19 2002-06-25 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
CN1412183A (en) 2001-10-15 2003-04-23 中国科学院上海药物研究所 New preparation method of timixatan
US20030139608A1 (en) 2002-01-18 2003-07-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing and purifying 1,7' -dimethyl-2' -propyl-2,5'-bi-1H-benzimidazole
WO2004108686A2 (en) 2003-06-06 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds having hypoglycemic activity
WO2006044648A1 (en) 2004-10-15 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing telmisartan
US20070037986A1 (en) 2005-07-22 2007-02-15 Helmut Heitger Preparation of 1,7,'-dimethyl-2'-propyl-2,5'-bi-1H-benzimidazole
WO2009133122A1 (en) 2008-05-02 2009-11-05 Boehringer Ingelheim International Gmbh Production of 1,7´-dimethyl-2´-propyl-2,5´-bi-1h-benzimidazole

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US6410742B1 (en) 1999-01-19 2002-06-25 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
WO2000063158A1 (en) 1999-04-17 2000-10-26 Boehringer Ingelheim Pharma Kg Method for nitrating aniline derivatives
CN1344712A (en) 2001-07-30 2002-04-17 中国科学院上海药物研究所 Synthesis path of Timisatem
CN1412183A (en) 2001-10-15 2003-04-23 中国科学院上海药物研究所 New preparation method of timixatan
US20030139608A1 (en) 2002-01-18 2003-07-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing and purifying 1,7' -dimethyl-2' -propyl-2,5'-bi-1H-benzimidazole
WO2004108686A2 (en) 2003-06-06 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole compounds having hypoglycemic activity
WO2006044648A1 (en) 2004-10-15 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing telmisartan
US20070037986A1 (en) 2005-07-22 2007-02-15 Helmut Heitger Preparation of 1,7,'-dimethyl-2'-propyl-2,5'-bi-1H-benzimidazole
WO2009133122A1 (en) 2008-05-02 2009-11-05 Boehringer Ingelheim International Gmbh Production of 1,7´-dimethyl-2´-propyl-2,5´-bi-1h-benzimidazole

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HYDRAZINE/RANEY NI JOURNAL OF HETEROCYCLIC CHEMISTRY vol. 40, 2003, pages 1107 - 1112
J. MED. CHEM. vol. 36, no. 25, 1993, pages 4040 - 51
ORGANIC PROCESS RESEARCH & DEVELOPMENT vol. 11, 2007, pages 81 - 85

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014067237A1 (en) * 2012-10-31 2014-05-08 上海特化医药科技有限公司 Telmisartan preparation method and intermediate thereof
CN103787982A (en) * 2012-10-31 2014-05-14 上海特化医药科技有限公司 Telmisartan preparation method and intermediate of telmisartan
CN104768936A (en) * 2012-10-31 2015-07-08 上海特化医药科技有限公司 Enzalutamide polymorphic forms and its preparation
CN104768936B (en) * 2012-10-31 2017-07-28 上海特化医药科技有限公司 Prepare the method and its intermediate of Telmisartan
JP2015160810A (en) * 2014-02-26 2015-09-07 株式会社トクヤマ METHOD OF PRODUCING 4-METHYL-6(1-METHYLBENZIMIDAZOL-2-YL)-2-n-PROPYL-1H-BENZIMIDAZOLE
CN104974096A (en) * 2015-07-07 2015-10-14 威海迪嘉制药有限公司 Preparation method of telmisartan intermediate
CN104974096B (en) * 2015-07-07 2019-02-01 威海迪素制药有限公司 A kind of preparation method of telmisartan intermediate

Also Published As

Publication number Publication date
WO2012028925A3 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
US20030232987A1 (en) Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
KR101342241B1 (en) Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US20070185333A1 (en) Process for the Preparation of 4-(Benzimidazolylmethylamino)-Benzamides and the Salts Thereof
CN101023070B (en) Method for the production of dihydropteridinones
JPH07224059A (en) Condensed imidazole compound
EP0260817A1 (en) Quinazolinediones and pyridopyrimidinediones
US20050159605A1 (en) Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
CN1768044A (en) Process for manufacture of telmisartan
ES2487215T3 (en) Improved process
US7329747B2 (en) Synthesis of olanzapine and intermediates thereof
US8741920B2 (en) Process for the manufacture of pharmaceutically active compounds
KR101183034B1 (en) Process for the preparation of telmisartan
KR20100069675A (en) Process and intermediates for preparing integrase inhibitors
CZ2005507A3 (en) Process for preparing oxycodone
EP0300614A1 (en) Process for the preparation of substituted indolinone derivatives
HU192398B (en) Process for producing derivatives of quinoline-carboxylic acids and pharmaceutical compositions of antibacterial activity containing them
WO2006044754A2 (en) Process for preparing telmisartan
KR20090079189A (en) Process for the synthesis of cmhtp and intermediates thereof
RU2397981C2 (en) 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide synthesis method
US7692027B2 (en) Process for the preparation of telmisartan
US20080269503A1 (en) Processes for preparing darifenacin hydrobromide
WO2011124704A1 (en) Process for preparing an intermediate for silodosin
US4018790A (en) Substituted 1-sulfonylbenzimidazoles
CN101817833B (en) DPP-IV inhibitor
EA011507B1 (en) A method for the preparation potassium salts of losartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11770155

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11770155

Country of ref document: EP

Kind code of ref document: A2